A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy
Tipus: ASSAIG CLÍNIC Autor: yolanda gonzalez montes Centre: Institut Català d'Oncologia (ICO)A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Tipus: ASSAIG CLÍNIC Autor: rosa coll jorda Centre: Institut Català d'Oncologia (ICO)A PHASE 3, MULTICENTER, OPEN-LABEL,RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FEDRATINIB COMPARED TO BEST AVAILABLE THERAPY IN SUBJECTS WITH DIPSSINTERMEDIATE OR HIGH-RISK PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS AND PREVIOUSLY TREATED WITH RUXOLITINIB
Tipus: ASSAIG CLÍNIC Autor: anna angona figueras Centre: Institut Català d'Oncologia (ICO)A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO R-CHOP VERSUS R-CHOP IN PREVIOUSLY UNTREATED, HIGH-INTERMEDIATE AND HIGH-RISK PATIENTS WITH NEWLY-DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Tipus: ASSAIG CLÍNIC Autor: nichollas john kelleher Centre: Institut Català d'Oncologia (ICO)A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY
Tipus: ASSAIG CLÍNIC Autor: helena pla juher Centre: Institut Català d'Oncologia (ICO)A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with locally Advance Unresectable Pancreatic Cancer
Tipus: ASSAIG CLÍNIC Autor: adelaida garcia velasco Centre: Institut Català d'Oncologia (ICO)A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS).
Tipus: ASSAIG CLÍNIC Autor: lluÍs ramiÓ torrentÀ Centre: ICS-IAS UNIEM Unitat de Neuroimmunologia i Esclerosi Múltiple Territorial de Girona (UNIEMTG)A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis.
Tipus: ASSAIG CLÍNIC Autor: yolanda gonzalez montes Centre: Institut Català d'Oncologia (ICO)A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose od radium-223 dichloride vs. sandard doses of novel anti-hormonal therapy NAH in patients with bone dominant metastatic castration resistant prostate cancer mCRPC progressing on/after one line of NAS.
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A Phase I Dose Finding and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Tipus: ASSAIG CLÍNIC Autor: joaquim bosch barrera Centre: Institut Català d'Oncologia (ICO)A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based chemotherapy
Tipus: ASSAIG CLÍNIC Autor: nÚria sala gonzÁlez Centre: Institut Català d'Oncologia (ICO)A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
Tipus: ASSAIG CLÍNIC Autor: pilar barretina ginesta Centre: Institut Català d'Oncologia (ICO)